Clinical Drug Investigation

, Volume 25, Issue 8, pp 551–554 | Cite as

Rapid Reversible Coma with Intravenous Gamma-Hydroxybutyrate in a Moxifloxacin-Treated Patient

  • Gerd Koehler
  • Anika Haimann
  • Hermann Laferl
  • Christoph Wenisch
Case Report

Keywords

Carvedilol Moxifloxacin Flumazenil Mental Status Change Levothyroxine Sodium 

References

  1. 1.
    Childs SJ. Safety of the fluoroquinolone antibiotics: focus on molecular structure. Infect Urol 2000; 13(1): 3–10Google Scholar
  2. 2.
    DeSarro A, DeSarro G. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem 2001 Mar; 8(4): 371–84PubMedCrossRefGoogle Scholar
  3. 3.
    Fish DN. Fluoroquinolones: adverse effects and drug interactions. Pharmacotherapy 2001; 21 (10 Pt 2): 253S–72SPubMedCrossRefGoogle Scholar
  4. 4.
    Okun MS, Boothby LA, Bartfield RB, et al. GHB: an important pharmacologic and clinical update. J Pharm Pharm Sci 2001 May-Aug; 4(2): 167–75PubMedGoogle Scholar
  5. 5.
    Rodvold KA. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21 (10 Pt 2): 233S–52SPubMedCrossRefGoogle Scholar
  6. 6.
    Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003; 37: 1210–5PubMedCrossRefGoogle Scholar
  7. 7.
    Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20(4): 289–302PubMedCrossRefGoogle Scholar
  8. 8.
    Stass H, Kubitza D, Halabi A, et al. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction. Br J Clin Pharmacol 2002 Mar; 53(3): 232–7PubMedCrossRefGoogle Scholar
  9. 9.
    Stass H, Dammer S, Kubitza A, et al. Einfluss von Hämodialyse (HD) und kontinuierlicher ambulatorischer Peritonealdialyse (CAPD) auf die steady state Pharamkokinetik von Moxifloxacin. 3. Forschungswerkstatt Moxifloxacin, Wuppertal, November 2002, Abstrakt 664Google Scholar
  10. 10.
    Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981 Aug; 30(2): 239–45PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Gerd Koehler
    • 1
  • Anika Haimann
    • 1
  • Hermann Laferl
    • 2
  • Christoph Wenisch
    • 2
  1. 1.Department of Medicine, Infectious Disease and Intensive CareUniversity HospitalGrazAustria
  2. 2.Medizinische Abteilung mit Infektione und Tropenmedizin, SMZ SüdKaiser Franz Josef SpitalWienAustria

Personalised recommendations